

**CONTACT - Media:**

Amsterdam +31.20.721.4488  
Lisbon +351.217.900.029

Brussels +32.2.620.15.50  
Paris +33.1.70.48.24.45

**CONTACT - Investor Relations:**

+33.1.70.48.24.17

## **ENTERNEXT WELCOMES KIADIS PHARMA ON EURONEXT AMSTERDAM AND EURONEXT BRUSSELS**

**Kiadis Pharma raises € 32.7 million in successful IPO**



**Amsterdam, Brussels – 2 July 2015** – EnterNext, the Euronext subsidiary designed to promote and grow the market for SMEs, today welcomed Kiadis Pharma on the Amsterdam and Brussels market of Euronext (ticker code: KDS).

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company is committed to developing innovative and potentially life-saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.

The total offering of Kiadis Pharma was valued at € 32.7 million. After opening, the market price was € 12.50 per share. Based on the opening price, the total market capitalization of the company was approximately € 166.4 million.

Manfred Rüdiger, CEO Kiadis Pharma, said: *“We are delighted to have joined Euronext today. Kiadis Pharma’s IPO received significant interest from local, European and US investors and now we intend to advance our pipeline of products that will potentially save the lives of thousands of blood cancer and inherited blood disorder patients.”*

*“We would like to congratulate Kiadis Pharma on its successful IPO”,* said Maurice van Tilburg, CEO of Euronext Amsterdam. *“It is great to see another biopharmaceutical company list on our markets. This transaction confirms the stockmarket’s appeal for biotech companies, allowing them to raise the capital they need to step up the pace of development.”*

Vincent van Dessel, CEO Euronext Brussels, added: *“We are delighted to welcome Kiadis Pharma today to Euronext, Europe’s most active market for life sciences. Through EnterNext we are fully committed to support the company in its objective to become a leading biopharmaceutical company focused on developing and commercialising therapeutic products in cell-based immunotherapy.”*

To celebrate the listing, CEO of Kiadis Pharma Manfred Rüdiger sounded the gong in Amsterdam to open trading on Euronext’s markets.



## CONTACTS –

### Kiadis Pharma

Consilium Strategic Communications  
 Mary-Jane Elliott, Lindsey Neville, Hendrik Thys  
 Tel: +44 (0) 203 709 5708  
[Kiadis@consilium-comms.com](mailto:Kiadis@consilium-comms.com)

Ian Bickerton, Christa Nooitgedagt  
 HuijskensBickerton  
 Tel. +31 (0) 20 685 5955  
[ian@huijskensbickerton.com](mailto:ian@huijskensbickerton.com)

### Euronext

Alice Jentink (Amsterdam): +31 2 0721 44 88; [ajentink@euronext.com](mailto:ajentink@euronext.com)  
 Pascal Brabant (Brussels): +32 2 620 15 50; [pbrabant@euronext.com](mailto:pbrabant@euronext.com)

### About Kiadis Pharma

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT). Although currently not a viable option for many patients, HSCT is generally regarded as the most effective curative approach to blood cancers and inherited blood disorders. The Company expects that HSCT could become a first-choice treatment for blood cancers and inherited blood disorders once current risks and limitations are addressed, thereby meeting a significant unmet medical need with its products.

Currently, ATIR™101 is being tested in an open-label Phase II trial in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT.

Kiadis Pharma is supported by a strong group of leading international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM. Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at: [www.Kiadis.com](http://www.Kiadis.com)

### About EnterNext

Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalisations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs. EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level.

### About Euronext

Euronext is the primary exchange in the Euro zone with more than 1 300 listed issuers worth €3.2 trillion in market capitalization, an unmatched blue chip franchise consisting of 24 issuers in the EURO STOXX 50® benchmark and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs' access to capital markets.

**Disclaimer**

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided "as is" without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at [www.euronext.com/terms-use](http://www.euronext.com/terms-use).

© 2015, Euronext N.V. - All rights reserved.